Debra Resta

12.2k total citations · 4 hit papers
24 papers, 9.0k citations indexed

About

Debra Resta is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Debra Resta has authored 24 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 14 papers in Genetics and 9 papers in Rheumatology. Recurrent topics in Debra Resta's work include Chronic Lymphocytic Leukemia Research (13 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Eosinophilic Disorders and Syndromes (9 papers). Debra Resta is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Eosinophilic Disorders and Syndromes (9 papers). Debra Resta collaborates with scholars based in United States, Switzerland and Germany. Debra Resta's co-authors include Moshe Talpaz, Brian Druker, Renaud Capdeville, Charles L. Sawyers, Hagop M. Kantarjian, J. Ford, Bin Peng, Nicholas Lydon, Elisabeth Buchdunger and Sayuri Ohno-Jones and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Debra Resta

24 papers receiving 8.7k citations

Hit Papers

Efficacy and Safety of a Specific Inhibitor of the BCR-AB... 2001 2026 2009 2017 2001 2001 2002 2007 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
    2001 3.8k citations Brian Druker, Moshe Talpaz et al. New England Journal of Medicine profile →
  2. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
    2001 2.1k citations Brian Druker, Charles L. Sawyers et al. New England Journal of Medicine profile →
  3. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
    2002 1.5k citations Hagop Kantarjian, Charles L. Sawyers et al. New England Journal of Medicine profile →
  4. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    2007 540 citations Hagop M. Kantarjian, Francis J. Giles et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Debra Resta United States 15 6.2k 4.4k 3.1k 2.0k 1.8k 24 9.0k
Nicholas Lydon Switzerland 29 7.2k 1.2× 4.8k 1.1× 3.3k 1.1× 3.9k 2.0× 2.7k 1.5× 40 12.6k
Junia V. Melo United Kingdom 49 7.3k 1.2× 5.6k 1.3× 3.2k 1.0× 2.7k 1.4× 1.8k 1.0× 119 10.2k
Renaud Capdeville Switzerland 29 6.8k 1.1× 5.0k 1.1× 3.3k 1.1× 3.0k 1.5× 2.8k 1.6× 52 13.0k
Sayuri Ohno-Jones United States 8 3.8k 0.6× 2.5k 0.6× 1.8k 0.6× 1.6k 0.8× 1.3k 0.7× 8 6.2k
Susan Branford Australia 43 9.7k 1.6× 8.1k 1.8× 5.3k 1.7× 1.1k 0.6× 1.3k 0.7× 200 11.0k
Susan O’Brien United States 34 4.4k 0.7× 3.5k 0.8× 1.9k 0.6× 867 0.4× 1.0k 0.6× 73 5.9k
Claudia Schoch Germany 56 8.9k 1.4× 3.4k 0.8× 1.0k 0.3× 5.1k 2.6× 1.3k 0.7× 194 11.4k
Michael J. Mauro United States 40 3.9k 0.6× 3.1k 0.7× 2.1k 0.7× 825 0.4× 918 0.5× 234 5.3k
Claude Preudhomme France 62 9.4k 1.5× 4.4k 1.0× 922 0.3× 5.7k 2.9× 2.4k 1.3× 356 13.3k
Miloslav Beran United States 46 5.2k 0.8× 3.4k 0.8× 736 0.2× 2.2k 1.1× 1.8k 1.0× 106 8.5k

Countries citing papers authored by Debra Resta

Since Specialization
Citations

This map shows the geographic impact of Debra Resta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra Resta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra Resta more than expected).

Fields of papers citing papers by Debra Resta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra Resta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra Resta. The network helps show where Debra Resta may publish in the future.

Co-authorship network of co-authors of Debra Resta

This figure shows the co-authorship network connecting the top 25 collaborators of Debra Resta. A scholar is included among the top collaborators of Debra Resta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra Resta. Debra Resta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Peng, Bin, Michael Hayes, Debra Resta, et al.. (2004). Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients. Journal of Clinical Oncology. 22(5). 935–942. 371 indexed citations
3.
Kantarjian, Hagop M., Moshe Talpaz, Susan O’Brien, et al.. (2003). The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 100(1). 116–121. 93 indexed citations
4.
Resta, Debra, Martin S. Tallman, John L. Frater, et al.. (2003). Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec): Bone Marrow Histopathology and Correlation With Genetic Status. American Journal of Clinical Pathology. 119(6). 833–841. 15 indexed citations
5.
Frater, John L., Martin S. Tallman, Daina Variakojis, et al.. (2003). Chronic Myeloid Leukemia Following Therapy with Imatinib Mesylate (Gleevec). American Journal of Clinical Pathology. 119(6). 833–841. 29 indexed citations
6.
Gotlib, Jason, Caroline Berube, Jianhua Ruan, et al.. (2003). PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficacy in mast cell leukemia with the D816V KIT mutation.. 6 indexed citations
7.
Kantarjian, Hagop M., Susan O’Brien, Jörge E. Cortes, et al.. (2002). Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.. PubMed. 8(7). 2167–76. 85 indexed citations
8.
Kantarjian, Hagop, Charles L. Sawyers, Andreas Hochhaus, et al.. (2002). Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. New England Journal of Medicine. 346(9). 645–652. 1517 indexed citations breakdown →
9.
Kantarjian, Hagop M., Jörge E. Cortes, Susan O’Brien, et al.. (2002). Imatinib mesylate (STI571) therapy for Philadelphia chromosome–positive chronic myelogenous leukemia in blast phase. Blood. 99(10). 3547–3553. 227 indexed citations
10.
Zubay, Geoffrey, Brian Druker, Moshe Talpaz, et al.. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympoblastic leukemia with the philadelphia chromosome. 14(13). 733–738. 9 indexed citations
11.
Druker, Brian, Moshe Talpaz, Debra Resta, et al.. (2001). Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. New England Journal of Medicine. 344(14). 1031–1037. 3811 indexed citations breakdown →
12.
Druker, Brian, Charles L. Sawyers, Hagop M. Kantarjian, et al.. (2001). Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome. New England Journal of Medicine. 344(14). 1038–1042. 2070 indexed citations breakdown →
13.
Druker, Brian, Moshe Talpaz, Debra Resta, et al.. (2000). Bcr-abl kinase inhibition as the basis of therapy for cml. Experimental Hematology. 28(7). 130–130. 1 indexed citations
14.
Rosenfeld, C, Brian J. Bolwell, Ann V. LeFever, et al.. (1996). Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.. PubMed. 17(2). 179–83. 26 indexed citations
15.
Huhn, Richard D., Edward J. Yurkow, Robert Tushinski, et al.. (1996). Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers.. PubMed. 24(7). 839–47. 34 indexed citations
16.
Rinehart, J. J., Kim Margolin, Pierre L. Triozzi, et al.. (1995). Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.. PubMed. 1(10). 1139–44. 3 indexed citations
17.
Scadden, David T., et al.. (1995). In Vivo Effects of Interleukin 3 in HIV Type 1-Infected Patients with Cytopenia. AIDS Research and Human Retroviruses. 11(6). 731–740. 8 indexed citations
18.
Huhn, Richard D., Edward J. Yurkow, John G. Kuhn, et al.. (1995). Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers*. Clinical Pharmacology & Therapeutics. 57(1). 32–41. 7 indexed citations
19.
Tepler, I, Anthony Elias, Leslie A. Kalish, et al.. (1994). Effect of recombinant human interleukin‐3 on haematological recovery from chemotherapy‐induced myelosuppression. British Journal of Haematology. 87(4). 678–686. 14 indexed citations
20.
Nemunaitis, John, FR Appelbaum, Jack W. Singer, et al.. (1993). Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. Blood. 82(11). 3273–3278. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicholas Lydon Breakdown of academic impact, for papers by Junia V. Melo Breakdown of academic impact, for papers by Renaud Capdeville Breakdown of academic impact, for papers by Sayuri Ohno-Jones Breakdown of academic impact, for papers by Susan Branford Breakdown of academic impact, for papers by Susan O’Brien Breakdown of academic impact, for papers by Claudia Schoch Breakdown of academic impact, for papers by Michael J. Mauro Breakdown of academic impact, for papers by Claude Preudhomme Breakdown of academic impact, for papers by Miloslav Beran
Rankless by CCL
2026